Modified Poly(A) Structure for Stable mRNA Translation

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Natural poly(A) sequences in mRNA exhibit instability and variability, leading to inconsistent translation efficiency and stability, which complicates mRNA drug development and quality control.

Innovation Solution

A modified poly(A) polynucleotide with specific nucleotide configurations, including at least two R elements of A nucleotides and one or more S elements, is introduced to stabilize mRNA and enhance translation efficiency.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If natural poly(A) is used in mRNA, then the mRNA can be synthesized and translated, but the poly(A) length varies randomly causing instability and inconsistent translation efficiency

Engineering Contradiction:
ImprovemRNA stability and translation efficiency consistencyVSAvoidpoly(A) length stability
Core Design Contradiction:
ReliabilityVSStability of the object's composition

Solution Approach 1:

The poly(A) sequence is divided into multiple A blocks separated by non-A nucleotides (S elements). Each A block contains a specific number of A nucleotides (e.g., 6-12 A's), and they are separated by S elements consisting of 1-4 non-A nucleotides. This segmentation prevents random length variation while maintaining the functional properties of poly(A) for mRNA stability and translation efficiency.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention changes the parameters of poly(A) by introducing a defined structure with specific numbers of A nucleotides in each block (6-12), specific lengths of S elements (1-4 non-A nucleotides), and a total poly(A) length of 30-150 nucleotides. This parameter control ensures consistent poly(A) length across different mRNA molecules, resolving the randomness issue of natural poly(A).

Inventive Principle:
Principle #35Parameter changes

2Reliability

If modified poly(A) with specific structure is introduced, then mRNA stability and translation efficiency are improved, but the poly(A) structure becomes more complex

Engineering Contradiction:
ImprovemRNA stability and translation efficiencyVSAvoidpoly(A) structure complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The poly(A) sequence is divided into multiple A blocks separated by non-A nucleotides (S elements). Each A block contains a specific number of A nucleotides (e.g., 6-12 A's), and they are separated by S elements consisting of 1-4 non-A nucleotides. This segmentation prevents random length variation while maintaining the functional properties of poly(A) for mRNA stability and translation efficiency.

Inventive Principle:
Principle #1Segmentation

Solution Approach 2:

The invention changes the parameters of poly(A) by introducing a defined structure with specific numbers of A nucleotides in each block (6-12), specific lengths of S elements (1-4 non-A nucleotides), and a total poly(A) length of 30-150 nucleotides. This parameter control ensures consistent poly(A) length across different mRNA molecules, resolving the randomness issue of natural poly(A).

Inventive Principle:
Principle #35Parameter changes

Data Source

PatentEP4692345A1Polynucleotide molecule comprising poly(a) and use thereof
Publication Date: 2026.02.11 SHENZHEN SHENXIN BIOTECHNOLOGY CO LTD
  • EP4692345A1 patent drawingFigure 1~2
  • EP4692345A1 patent drawingFigure 3~4
  • EP4692345A1 patent drawingFigure 5~6

AI summary

A polynucleotide, the polynucleotide comprising a modified poly(A) having at least 30 nucleotides. The modified poly(A) comprises: i) at least two R elements, the R elements being defined as polynucleotide composed of A nucleotide; and ii) at least one S element. The S element: a) is a nucleotide that is not an A nucleotide, or b) is composed of at least two nucleotides, and the nucleotides at both ends are not A nucleotide. The total number of S elements is one less than the total number of R elements, the S elements are connected to the R elements, and each S element is flanked by the R elements. The present invention also relates to a vector and a host cell comprising the polynucleotide, a method for using the polynucleotide to prepare RNA and the RNA prepared therefrom, a pharmaceutical composition or LNP comprising the polynucleotide, the RNA, the vector, and/or the host cell, and a use thereof.